What is the recommended workup for an inpatient presenting with chest pain?

Inpatient Chest Pain Workup

For an inpatient presenting with chest pain, immediately obtain a 12-lead ECG (within minutes of presentation), perform serial troponin measurements (high-sensitivity troponin at 0 and 1-3 hours, or conventional troponin at 0 and 3-6 hours), obtain a chest radiograph, and risk-stratify the patient using a validated clinical decision pathway to determine disposition and further testing needs. 1

Initial Immediate Workup (First Hour)

ECG Assessment

• Obtain a 12-lead ECG immediately upon presentation 1
• If the initial ECG is nondiagnostic but clinical suspicion for ACS remains intermediate-to-high, obtain supplemental leads V7-V9 to rule out posterior MI 1
• Perform serial ECGs if the initial ECG is nondiagnostic, especially when symptoms persist or clinical condition deteriorates 1
• If ECG shows STEMI, activate STEMI protocols immediately and proceed to invasive coronary angiography 1

Cardiac Biomarkers

The troponin sampling strategy depends on your institution's assay type:

• High-sensitivity troponin: Repeat at 1-3 hours after initial sample 1
• Conventional troponin: Repeat at 3-6 hours after initial sample 1
• For patients with symptoms beginning ≥3 hours before arrival, a normal ECG, and a single high-sensitivity troponin below the limit of detection may be reasonable to exclude myocardial injury 1

Chest Radiograph

• Obtain a chest X-ray to evaluate for alternative cardiac, pulmonary, and thoracic causes of symptoms (pneumothorax, pneumonia, aortic dissection, pleural effusion) 1

Risk Stratification and Subsequent Management

Risk Categorization

Use a validated clinical decision pathway to categorize patients into risk strata based on clinical presentation, ECG findings, troponin results, age, symptoms, and CAD risk factors 1:

Low-Risk Patients (<1% 30-day risk of death or MACE):

• Defer further testing or consider optional testing (ECG monitoring, coronary artery calcium scan) 1
• Can be discharged with outpatient follow-up in 1-2 weeks 2
• Do not routinely perform stress testing or coronary CTA before discharge in low-risk patients with negative troponins 2

Intermediate-Risk Patients:

• Proceed to anatomic or functional testing 1
• Choice depends on clinical question: coronary CTA to define anatomy vs. stress testing to assess ischemia severity
• Consider stress testing particularly for patients with abnormal resting ECG or inability to perform maximal exercise 1

High-Risk Patients:

• Proceed directly to invasive coronary angiography 1
• Maintain continuous monitoring
• Transfer to facility with cardiac catheterization capabilities if not available

Critical Pitfalls to Avoid

Common Mistakes:

• Failing to obtain posterior leads (V7-V9) in patients with high suspicion but nondiagnostic initial ECG—posterior MI is easily missed 1
• Using incorrect troponin timing intervals for your institution's assay type—this leads to premature rule-out 1
• Over-testing low-risk patients after negative serial troponins—this increases costs without reducing 30-day MACE 2
• Ignoring previous testing—incorporate prior stress tests, angiography, or coronary CTA results into decision-making 1

Special Considerations:

• Patients with previous angiography showing no occlusive CAD (0% stenosis) within 5 years should be referred for expedited outpatient testing rather than inpatient evaluation 2
• Patients with previous coronary CTA within 2 years showing no stenoses require only a single high-sensitivity troponin below threshold to exclude ACS 2
• Consider screening for depression and anxiety in patients with recurrent low-risk chest pain, as this affects healthcare utilization 2

Implementation Strategy

Your institution must have a standardized clinical decision pathway that includes:

• Protocol for troponin sampling based on your specific assay 1
• Clear risk stratification criteria
• Defined pathways for each risk category
• Integration of previous testing results 1

This algorithmic approach prioritizes selective testing, optimizes lower-cost evaluations, reduces unnecessary layered testing, and defers testing when diagnostic yield is low 1.